Related Experiment Video
Updated: Jul 31, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Perspective: Hepatocyte-Directed Base Editing as Novel Treatment for Human Dyslipidemia-Current Status and Remaining
Menno Hoekstra1,2, Miranda Van Eck1,2,3, Theo J C Van Berkel1
1Division of BioTherapeutics (M.H., M.V.E., T.J.C.V.B.), Leiden Academic Centre for Drug Research, Leiden University, The Netherlands.
Abstract:
Hyperlipidemia is a major risk factor for the development of atherosclerotic cardiovascular disease. Lipid-lowering drug therapies therefore still form the heart of the ongoing battle against the occurrence of cardiovascular events. However, in light of the important improvements in gene interference and editing that have been made during the last 2 decades, gene therapy-the genetic modification of cells to produce a permanent therapeutic effect-is currently employed to relief hypercholesterolemic subjects from their potential (chronic) cardiovascular disease burden. In this perspective, we review the current status regarding hepatocyte-directed base editing to treat human dyslipidemia and provide suggestions for further technological improvement.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
RNA Editing

